A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Trial Profile

A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2016

At a glance

  • Drugs Vismodegib (Primary) ; Cyclophosphamide; Epirubicin; Granulocyte-macrophage colony-stimulating factors; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms SHH-CM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top